Euromoney: H1 Performance Encouraging; Sees FY Results In Line With Board's Expectations

Euromoney Institutional Investor PLC (ERM.L) said the Group delivered further strong revenue growth during the second quarter driven by continued momentum in subscriptions and the continuing recovery in events. Looking forward, the Group said it remains well placed to deliver full year results in line with the Board's expectations, before taking account of the benefits from property savings.

Euromoney noted that it has limited exposure to customers in Russia and Ukraine. The Group confirmed that it has suspended business with individuals who are incorporated or resident in Russia or Belarus.

Euromoney also said it expects People Intelligence to continue delivering double-digit revenue growth and are targeting approximately $100 million of revenue in fiscal 2025. People Intelligence is part of Euromoney's FPS division, accounting for over 40% of its subscription revenue in fiscal 2021. Euromoney targets People Intelligence to achieve improvement in operating margin to mid-30s percent by fiscal 2025, approximately double the adjusted operating margin achieved in fiscal 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT